Answers are grounded in this paper and cite their sources.
The use of circulating biochemical molecular markers in head and neck cancer holds the promise of improved diagnostics, treatment planning, and posttreatment surveillance. In this review, we provide an introduction for the head and neck surgeon of the basic science, current evidence, and future applications of circulating tumor DNA (ctDNA) as a biomarker and liquid biopsy to detect tumor genetic heterogeneity in patients with head and neck squamous cell carcinoma (HNSCC).
No takes yet. Share an insight, caveat, or question.
Spruce et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: